Checkpoint inhibitors are being used for a growing number of oncologic indications. As we learn more about these agents, we learn more about their associated adverse events. Endocrine and rheumatologic adverse events are well documented, and clinicians need to be well-versed in their assessment, diagnosis, and management. This webinar provides an overview of endocrine and rheumatologic immune-related adverse events, their assessment and grading, as well as management and practice pearls.
The course is offered on demand. Instructions on how to immediately access the course will be sent to you in an automatically generated email receipt after you register.
You will enjoy access for 90 days from date of purchase, after which you will no longer be able to access the course.
Cancer Treatment; Immunotherapy; Immune-Related Adverse Events; Checkpoint Inhibitors
Learner will describe the endocrine and rheumatologic effects of checkpoint inhibitors used in the management of cancer.
Nurses involved in the care of patients with cancer.
Up to 0.5 ILNA points may be applied to Treatment OR Survivorship OR Advanced Practice Roles. No more than 0.5 total points may be claimed for the program.